September 13, 2012 – Angiotensin-receptor blocker (ARB) therapy may cut the risk of Alzheimer's disease (AD) by reducing amyloid deposition in the brain, a new study hints.
The study, based on aggregated data and brain autopsies from 890 patients from 29 AD centers in the United States, showed that ARB treatment correlated with less amyloid accumulation and AD-related abnormality independent of other AD risk factors.
"To our knowledge, this is the first human evidence to suggest that treatment with ARBs may have a selective beneficial effect on amyloid metabolism," Ihab Hajjar, MD, and colleagues from University of Southern California, Los Angeles, report.
Their findings were published online September 10 in Archives of Neurology./.../
No comments:
Post a Comment